Exelixis, Inc. (EXEL)
Nasdaq: EXEL · Biological Products, (No Diagnostic Substances) · Alameda, CA · filing with the SEC since 2000
Grade7.5
◀ Past 8.6● Present 8.5▶ Future 5.1
Who owns Exelixis, Inc.
As filed with the SECHolders of 5% or more
4
Blackrock, Inc. holds 10.2% of Common Stock, as its SCHEDULE 13G/A filed Apr 28, 2025 says.
Directors and officers
16
report now, of 28 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 28, 2025 · Common Stock
Dapice Joshua J.
SCHEDULE 13D/A · filed Jan 5, 2026 · Common Stock, par value $0.001 per share (the "Shares") · 6.8% in May 20, 2025
Farallon Capital Management, L.L.C.
SCHEDULE 13D/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share (the "Shares")
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
AQR Capital Management, LLC
SCHEDULE 13G/A · filed Aug 12, 2026 · Common Stock, $0.001 Par Value per Share · reported falling below 5%, from 5.09% in Feb 13, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What EXEL reports owning in othersstakes of 5% or more, and other ties
3 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 10, 2026.
Insider tradesForm 4
32sales
1purchases
7sales on a scheduled plan
12people selling
$42.2Msold, in dollars
$1.2Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window13 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Aftab Dana | EVP, Research and Development | 4 | $7.7M | 0 | 0 | $0 |
| Haley Patrick J. | EVP, Commercial | 7 | $7.6M | 0 | 0 | $0 |
| Smith Julie | director | 3 | $4.7M | 0 | 0 | $0 |
| Senner Christopher J. | EVP and CFO | 3 | $4.6M | 0 | 0 | $0 |
| Wyszomierski Jack L | director | 2 | $4.6M | 2 | 0 | $0 |
| Papadopoulos Stelios | director | 1 | $4.4M | 0 | 0 | $0 |
| Poste George | director | 1 | $2.7M | 0 | 0 | $0 |
| Beckerle Mary C | director | 4 | $1.9M | 1 | 0 | $0 |
| Oliver Bob | director | 2 | $1.3M | 0 | 0 | $0 |
| Hefti Brenda | SVP and General Counsel | 2 | $1.2M | 2 | 0 | $0 |
| Freire Maria C | director | 1 | $900,000 | 0 | 0 | $0 |
| Eckhardt Sue Gail | director | 2 | $700,000 | 2 | 0 | $0 |
| Caligan Partners LP | director | 0 | $0 | 0 | 1 | $1.2M |